Retatrutide vs Semaglutide
Side-by-side comparison of Retatrutide, Semaglutide — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Retatrutide Retatrutide (GIP/GLP-1/Glucagon Triple Agonist) Weight Loss | Semaglutide Semaglutide (GLP-1 Receptor Agonist) Weight Loss |
|---|---|---|
| Basics | ||
| Molecular type | Triple GIP/GLP-1/Glucagon Receptor Agonist | GLP-1 Receptor Agonist |
| Amino acids | — | 31 |
| Molecular weight | — | 4,113.6 Da |
| Half-life | ~6 days | ~7 days |
| Route(s) | Subcutaneous injection | Subcutaneous injection, Oral (Rybelsus) |
| Mechanism & Research | ||
| Primary mechanism | Retatrutide activates three incretin and metabolic hormone receptors simultaneously. GLP-1 receptor agonism drives appetite suppression, slows gastric emptying, and reduces food intake — the primary mechanism shared with… | Semaglutide binds and activates GLP-1 receptors throughout the body with high affinity. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. These effects are glucose-depend… |
| Research status | Phase 3 Trial | FDA Approved |
| Evidence summary | Retatrutide is in Phase 3 clinical trials (NCT06052826) as of 2026, following highly positive Phase 2 data. The Phase 2 trial (NCT04881760, n=338) is the strongest weight loss signal from any pharmacological agent in hum… | Semaglutide has one of the most robust clinical trial programmes of any peptide compound. The STEP trial series (for weight management) and SUSTAIN series (for diabetes) collectively enrolled tens of thousands of partici… |
| Protocol & Dosing | ||
| Typical dose | 2mg → 12mg weekly (titration) | 0.25mg → 2.4mg weekly (weight management) |
| Frequency | Once weekly | Once weekly |
| Duration | Ongoing (Phase 3) | Ongoing (chronic management) |
| Timing | Same day each week | Same day each week, any time |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Not Prohibited |
| Deeper reading | ||
| Related peptides | Tirzepatide, Semaglutide, AOD-9604 | Tirzepatide, AOD-9604, Tesamorelin |
| Full profile | Read full Retatrutide profile → | Read full Semaglutide profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.